Login Register Cart 0
Generic placeholder image

Current Drug Research Reviews

Editor-in-Chief

ISSN (Print): 2589-9775
ISSN (Online): 2589-9783

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Use of Medications for the Treatment of Alcohol Dependence: A Retrospective Study Conducted in 2011-2012

Author(s): Roberta Agabio*, Silvia Balia, Gian Luigi Gessa and Pier Paolo Pani

Volume 13, Issue 2, 2021

Published on: 28 December, 2020

Page: [154 - 164] Pages: 11

DOI: 10.2174/2589977512666201228121820

Price: $65

Abstract

Background: Pharmacotherapy for Alcohol Dependence (AD) is underutilized. Barriers preventing the use of AD medications include high prices, lack of access to prescribing physicians, and a limited number of available medications.

Objective: The study evaluated the use of AD medications in a sample of Italian outpatients who received these medications free of charge, had access to physicians during office hours, and for whom substitution therapy [gamma-hydroxybutyrate (GHB)] was available. We also evaluated the rate of patients who received a combination of non-pharmacological and pharmacological treatments among participants who were still drinking.

Methods: SCID for AD and questionnaire were filled by to AD outpatients during a face-to-face interview.

Results & Discussion: 345 AD outpatients were interviewed: 58.8% were currently receiving at least one AD medication (GHB: 34.3%, disulfiram: 29.6%, acamprosate: 5.9%; naltrexone: 2.5%; more than one medication: 16.7%). Less than 30% of participants who were still drinking, received a combination of non-pharmacological and pharmacological treatments. Nonetheless, we found higher use of AD medications compared to previous studies conducted in other countries. This higher use of AD medications may be due to access to free medications, prescribing physicians’ style, and a larger number of available medications.

Conclusion: Our results confirm the underutilization of AD medications, as less than 60% of AD outpatients received medications, and less than 30% of those who were still drinking, received a combination of non-pharmacological and pharmacological treatments. These findings may be useful in improving our knowledge of the barriers that prevent the use of AD medications in clinical practice.

Keywords: Alcohol Dependence (AD), craving, pharmacotherapy, acamprosate, naltrexone, disulfiram, gamma-hydroxybutyrate.

« Previous Next »
Graphical Abstract

[1]
Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revision. Washington, DC: DSM-IV-TR 2000.
[2]
Grant BF, Goldstein RB, Saha TD, et al. Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry 2015; 72(8): 757-66.
[http://dx.doi.org/10.1001/jamapsychiatry.2015.0584] [PMID: 26039070]
[3]
Rehm J, Shield KD, Gmel G, Rehm MX, Frick U. Modeling the impact of alcohol dependence on mortality burden and the effect of available treatment interventions in the European Union. Eur Neuropsychopharmacol 2013; 23(2): 89-97.
[http://dx.doi.org/10.1016/j.euroneuro.2012.08.001] [PMID: 22920734]
[4]
American Psychiatric Association; Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA 2013.
[5]
Connor JP, Haber PS, Hall WD. Alcohol use disorders. Lancet 2016; 387(10022): 988-98. [Erratum in: Lancet 2016; 387: 944].
[http://dx.doi.org/10.1016/S0140-6736(15)00122-1] [PMID: 26343838]
[6]
Carvalho AF, Heilig M, Perez A, Probst C, Rehm J. Alcohol use disorders. Lancet 2019; 394(10200): 781-92.
[http://dx.doi.org/10.1016/S0140-6736(19)31775-1] [PMID: 31478502]
[7]
McCrady BS, Owens MD, Borders AZ, Brovko JM. Psychosocial approaches to alcohol use disorders since 1940: a review. J Stud Alcohol Drugs Suppl 2014; 75(Suppl. 17): 68-78.
[http://dx.doi.org/10.15288/jsads.2014.75.68] [PMID: 24565313]
[8]
Moos RH, Moos BS. Rates and predictors of relapse after natural and treated remission from alcohol use disorders. Addiction 2006; 101(2): 212-22.
[http://dx.doi.org/10.1111/j.1360-0443.2006.01310.x] [PMID: 16445550]
[9]
Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association Practice Guideline for the pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry 2018; 175(1): 86-90.
[http://dx.doi.org/10.1176/appi.ajp.2017.1750101] [PMID: 29301420]
[10]
Sinclair J, Chick J, Sørensen P, Kiefer F, Batel P, Gual A. Can alcohol dependent patients adhere to an ‘as-needed’ medication regimen? Eur Addict Res 2014; 20(5): 209-17.
[http://dx.doi.org/10.1159/000357865] [PMID: 24557083]
[11]
Dawson DA, Grant BF, Stinson FS, Chou PS. Estimating the effect of help-seeking on achieving recovery from alcohol dependence. Addiction 2006; 101(6): 824-34.
[http://dx.doi.org/10.1111/j.1360-0443.2006.01433.x] [PMID: 16696626]
[12]
Timko C, Debenedetti A, Moos BS, Moos RH. Predictors of 16-year mortality among individuals initiating help-seeking for an alcoholic use disorder. Alcohol Clin Exp Res 2006; 30(10): 1711-20.
[http://dx.doi.org/10.1111/j.1530-0277.2006.00206.x] [PMID: 17010138]
[13]
Saxon AJ, McCarty D. Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs. Pharmacol Ther 2005; 108(1): 119-28.
[http://dx.doi.org/10.1016/j.pharmthera.2005.06.014] [PMID: 16055196]
[14]
Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2007; 64(7): 830-42.
[http://dx.doi.org/10.1001/archpsyc.64.7.830] [PMID: 17606817]
[15]
Kranzler HR, Soyka M. Diagnosis and pharmacotherapy of alcohol use disorder: a review. JAMA 2018; 320(8): 815-24.
[http://dx.doi.org/10.1001/jama.2018.11406] [PMID: 30167705]
[16]
Knox J, Hasin DS, Larson FRR, Kranzler HR. Prevention, screening, and treatment for heavy drinking and alcohol use disorder. Lancet Psychiatry 2019; 6(12): 1054-67.
[http://dx.doi.org/10.1016/S2215-0366(19)30213-5] [PMID: 31630982]
[17]
Cohen E, Feinn R, Arias A, Kranzler HR. Alcohol treatment utilization: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend 2007; 86(2-3): 214-21.
[http://dx.doi.org/10.1016/j.drugalcdep.2006.06.008] [PMID: 16919401]
[18]
Grant BF, Chou SP, Saha TD, et al. Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001-2002 to 2012-2013: Results From the National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiatry 2017; 74(9): 911-23.
[http://dx.doi.org/10.1001/jamapsychiatry.2017.2161] [PMID: 28793133]
[19]
Grant BF, Dawson DA, Stinson FS, Chou SP, Dufour MC, Pickering RP. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend 2004; 74(3): 223-34.
[http://dx.doi.org/10.1016/j.drugalcdep.2004.02.004] [PMID: 15194200]
[20]
Alonso J, Angermeyer MC, Bernert S, et al. Use of mental health services in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004; 420(420): 47-54.
[PMID: 15128387]
[21]
Rehm J, Allamani A, Elekes Z, et al. Alcohol dependence and treatment utilization in Europe - a representative cross-sectional study in primary care. BMC Fam Pract 2015; 16: 90.
[http://dx.doi.org/10.1186/s12875-015-0308-8] [PMID: 26219430]
[22]
Rehm J, Allamani A, Della Vedova R, et al. General practitioners recognizing alcohol dependence: a large cross-sectional study in 6 European countries. Ann Fam Med 2015; 13(1): 28-32.
[http://dx.doi.org/10.1370/afm.1742] [PMID: 25583889]
[23]
Bramness JG, Mann K, Wurst FM. Marketing status and perceived efficacy of drugs for supporting abstinence and reducing alcohol intake in alcohol use disorders: a survey among European Federation of Addiction Societies in Europe. Eur Addict Res 2016; 22(6): 318-21.
[http://dx.doi.org/10.1159/000447965] [PMID: 27438908]
[24]
Oleski J, Mota N, Cox BJ, Sareen J. Perceived need for care, help seeking, and perceived barriers to care for alcohol use disorders in a national sample. Psychiatr Serv 2010; 61(12): 1223-31.
[http://dx.doi.org/10.1176/ps.2010.61.12.1223] [PMID: 21123407]
[25]
Dawson DA, Goldstein RB, Grant BF. Factors associated with first utilization of different types of care for alcohol problems. J Stud Alcohol Drugs 2012; 73(4): 647-56.
[http://dx.doi.org/10.15288/jsad.2012.73.647] [PMID: 22630803]
[26]
Edlund MJ, Booth BM, Han X. Who seeks care where? Utilization of mental health and substance use disorder treatment in two national samples of individuals with alcohol use disorders. J Stud Alcohol Drugs 2012; 73(4): 635-46.
[http://dx.doi.org/10.15288/jsad.2012.73.635] [PMID: 22630802]
[27]
Thompson A, Ashcroft DM, Owens L, van Staa TP, Pirmohamed M. Drug therapy for alcohol dependence in primary care in the UK: A Clinical Practice Research Datalink study. PLoS One 2017; 12(3): e0173272.
[http://dx.doi.org/10.1371/journal.pone.0173272] [PMID: 28319159]
[28]
Williams EC, Achtmeyer CE, Young JP, et al. Barriers to and facilitators of alcohol use disorder pharmacotherapy in primary care: a qualitative study in five VA clinics. J Gen Intern Med 2018; 33(3): 258-67.
[http://dx.doi.org/10.1007/s11606-017-4202-z] [PMID: 29086341]
[29]
Finlay AK, Ellerbe LS, Wong JJ, et al. Barriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs. J Subst Abuse Treat 2017; 77: 38-43.
[http://dx.doi.org/10.1016/j.jsat.2017.03.005] [PMID: 28476269]
[30]
Hermos JA, Young MM, Gagnon DR, Fiore LD. Patterns of dispensed disulfiram and naltrexone for alcoholism treatment in a veteran patient population. Alcohol Clin Exp Res 2004; 28(8): 1229-35.
[http://dx.doi.org/10.1097/01.ALC.0000134234.39303.17] [PMID: 15318122]
[31]
Harris AH, Kivlahan DR, Bowe T, Humphreys KN. Pharmacotherapy of alcohol use disorders in the Veterans Health Administration. Psychiatr Serv 2010; 61(4): 392-8.
[http://dx.doi.org/10.1176/ps.2010.61.4.392] [PMID: 20360279]
[32]
Harris AH, Oliva E, Bowe T, Humphreys KN, Kivlahan DR, Trafton JA. Pharmacotherapy of alcohol use disorders by the Veterans Health Administration: patterns of receipt and persistence. Psychiatr Serv 2012; 63(7): 679-85.
[http://dx.doi.org/10.1176/appi.ps.201000553] [PMID: 22549276]
[33]
Robinson S, Bowe T, Harris AH. Group management of pharmacotherapy for alcohol dependence: feasibility and impact on adoption. J Subst Abuse Treat 2013; 45(5): 475-7.
[http://dx.doi.org/10.1016/j.jsat.2013.06.009] [PMID: 23932227]
[34]
Rubinsky AD, Chen C, Batki SL, Williams EC, Harris AH. Comparative utilization of pharmacotherapy for alcohol use disorder and other psychiatric disorders among U.S. Veterans Health Administration patients with dual diagnoses. J Psychiatr Res 2015; 69: 150-7.
[http://dx.doi.org/10.1016/j.jpsychires.2015.07.016] [PMID: 26343607]
[35]
Mellinger JL, Scott Winder G, DeJonckheere M, et al. Misconceptions, preferences and barriers to alcohol use disorder treatment in alcohol-related cirrhosis. J Subst Abuse Treat 2018; 91: 20-7.
[http://dx.doi.org/10.1016/j.jsat.2018.05.003] [PMID: 29910011]
[36]
Williams EC, Lapham GT, Shortreed SM, et al. Among patients with unhealthy alcohol use, those with HIV are less likely than those without to receive evidence-based alcohol-related care: a national VA study. Drug Alcohol Depend 2017; 174: 113-20.
[http://dx.doi.org/10.1016/j.drugalcdep.2017.01.018] [PMID: 28324813]
[37]
Frost MC, Matson TE, Tsui JI, Williams EC. Influence of comorbid drug use disorder on receipt of evidence-based treatment for alcohol use disorder among VA patients with alcohol use disorder and Hepatitis C and/or HIV. Drug Alcohol Depend 2019; 194: 288-95.
[http://dx.doi.org/10.1016/j.drugalcdep.2018.10.008] [PMID: 30469100]
[38]
Owens MD, Chen JA, Simpson TL, Timko C, Williams EC. Barriers to addiction treatment among formerly incarcerated adults with substance use disorders. Addict Sci Clin Pract 2018; 13(1): 19.
[http://dx.doi.org/10.1186/s13722-018-0120-6] [PMID: 30126452]
[39]
Oliva EM, Maisel NC, Gordon AJ, Harris AH. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Curr Psychiatry Rep 2011; 13(5): 374-81.
[http://dx.doi.org/10.1007/s11920-011-0222-2] [PMID: 21773951]
[40]
Thomas SE, Miller PM. Knowledge and attitudes about pharmacotherapy for alcoholism: a survey of counselors and administrators in community-based addiction treatment centres. Alcohol Alcohol 2007; 42(2): 113-8.
[http://dx.doi.org/10.1093/alcalc/agl100] [PMID: 17172258]
[41]
Grant BF. Barriers to alcoholism treatment: reasons for not seeking treatment in a general population sample. J Stud Alcohol 1997; 58(4): 365-71.
[http://dx.doi.org/10.15288/jsa.1997.58.365] [PMID: 9203117]
[42]
Kranzler HR. Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research. Alcohol Alcohol 2000; 35(6): 537-47.
[http://dx.doi.org/10.1093/alcalc/35.6.537] [PMID: 11093959]
[43]
Mark TL, Kranzler HR, Poole VH, Hagen CA, McLeod C, Crosse S. Barriers to the use of medications to treat alcoholism. Am J Addict 2003; 12(4): 281-94. a
[http://dx.doi.org/10.1111/j.1521-0391.2003.tb00543.x] [PMID: 14504021]
[44]
Abraham AJ, Roman PM. Early adoption of injectable naltrexone for alcohol-use disorders: findings in the private-treatment sector. J Stud Alcohol Drugs 2010; 71(3): 460-6.
[http://dx.doi.org/10.15288/jsad.2010.71.460] [PMID: 20409441]
[45]
Greenfield SF, Brooks AJ, Gordon SM, et al. Substance abuse treatment entry, retention, and outcome in women: a review of the literature. Drug Alcohol Depend 2007; 86(1): 1-21.
[http://dx.doi.org/10.1016/j.drugalcdep.2006.05.012] [PMID: 16759822]
[46]
Terplan M, McNamara EJ, Chisolm MS. Pregnant and non-pregnant women with substance use disorders: the gap between treatment need and receipt. J Addict Dis 2012; 31(4): 342-9.
[http://dx.doi.org/10.1080/10550887.2012.735566] [PMID: 23244553]
[47]
Becker JB, McClellan M, Reed BG. Sociocultural context for sex differences in addiction. Addict Biol 2016; 21(5): 1052-9.
[http://dx.doi.org/10.1111/adb.12383] [PMID: 26935336]
[48]
Hagedorn HJ, Brown R, Dawes M, et al. Enhancing access to alcohol use disorder pharmacotherapy and treatment in primary care settings: ADaPT-PC. Implement Sci 2016; 11: 64.
[http://dx.doi.org/10.1186/s13012-016-0431-5] [PMID: 27164835]
[49]
Hagedorn HJ, Wisdom JP, Gerould H, et al. Implementing alcohol use disorder pharmacotherapy in primary care settings: a qualitative analysis of provider-identified barriers and impact on implementation outcomes. Addict Sci Clin Pract 2019; 14(1): 24.
[http://dx.doi.org/10.1186/s13722-019-0151-7] [PMID: 31291996]
[50]
Haley SJ, Pinsker EA, Gerould H, Wisdom JP, Hagedorn HJ. Patient perspectives on alcohol use disorder pharmacotherapy and integration of treatment into primary care settings. Subst Abus 2019; 40(4): 501-9.
[http://dx.doi.org/10.1080/08897077.2019.1576089] [PMID: 30829127]
[51]
Harris AHS, Brown R, Dawes M, et al. Effects of a multifaceted implementation intervention to increase utilization of pharmacological treatments for alcohol use disorders in the US Veterans Health Administration. J Subst Abuse Treat 2017; 82: 107-12.
[http://dx.doi.org/10.1016/j.jsat.2017.09.002] [PMID: 29021108]
[52]
Williams EC, Matson TE, Harris AHS. Strategies to increase implementation of pharmacotherapy for alcohol use disorders: a structured review of care delivery and implementation interventions. Addict Sci Clin Pract 2019; 14(1): 6.
[http://dx.doi.org/10.1186/s13722-019-0134-8] [PMID: 30744686]
[53]
Caputo F, Vignoli T, Grignaschi A, Cibin M, Addolorato G, Bernardi M. Pharmacological management of alcohol dependence: from mono-therapy to pharmacogenetics and beyond. Eur Neuropsychopharmacol 2014; 24(2): 181-91.
[http://dx.doi.org/10.1016/j.euroneuro.2013.10.004] [PMID: 24182622]
[54]
Campbell EJ, Lawrence AJ, Perry CJ. New steps for treating alcohol use disorder. Psychopharmacology (Berl) 2018; 235(6): 1759-73.
[http://dx.doi.org/10.1007/s00213-018-4887-7] [PMID: 29574507]
[55]
Agabio R, Carai MAM, Gessa GL, Colombo G. Encyclopedia of Behavioral Neuroscience. Oxford: Academic Press. Gamma-Hydroxybutyric Acid (GHB) 2010; pp. 76-83.
[56]
Chick J, Nutt DJ. Substitution therapy for alcoholism: time for a reappraisal? J Psychopharmacol 2012; 26(2): 205-12.
[http://dx.doi.org/10.1177/0269881111408463] [PMID: 21742726]
[57]
Carter LP, Pardi D, Gorsline J, Griffiths RR. Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse. Drug Alcohol Depend 2009; 104(1-2): 1-10.
[http://dx.doi.org/10.1016/j.drugalcdep.2009.04.012] [PMID: 19493637]
[58]
van Amsterdam JG, Brunt TM, McMaster MT, Niesink RJ. Possible long-term effects of γ-hydroxybutyric acid (GHB) due to neurotoxicity and overdose. Neurosci Biobehav Rev 2012; 36(4): 1217-27.
[http://dx.doi.org/10.1016/j.neubiorev.2012.02.002] [PMID: 22342779]
[59]
Leone MA, Vigna-Taglianti F, Avanzi G, Brambilla R, Faggiano F. Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database Syst Rev 2010; 17(2): CD006266.
[http://dx.doi.org/10.1002/14651858.CD006266.pub2] [PMID: 20166080]
[60]
Trogu E, Vacca R, Agabio R, Carta I, Pani PP, Siza R. Rapporto regionale sullo stato delle dipendenze in Sardegna 2008. Available from: http://www.sardegnasalute.it/documenti/9_46_20080915131634.pdf
[61]
Agabio R, Trogu E, Pani PP, Pani PP. Antidepressants for the treatment of people with co-occurring depression and alcohol dependence. Cochrane Database Syst Rev 2018; 4(4): CD008581.
[http://dx.doi.org/10.1002/14651858.CD008581.pub2] [PMID: 29688573]
[62]
Agabio R, Leggio L. HIV and alcohol use disorder: we cannot ignore the elephant in the room. Lancet HIV 2019; 6(8): e485-6.
[http://dx.doi.org/10.1016/S2352-3018(19)30074-8] [PMID: 31109914]
[63]
Mark TL, Kranzler HR, Song X, Bransberger P, Poole VH, Crosse S. Physicians’ opinions about medications to treat alcoholism. Addiction 2003; 98(5): 617-26. b
[http://dx.doi.org/10.1046/j.1360-0443.2003.00377.x] [PMID: 12751979]
[64]
Mark TL, Kranzler HR, Song X. Understanding US addiction physicians’ low rate of naltrexone prescription. Drug Alcohol Depend 2003; 71(3): 219-28. c
[http://dx.doi.org/10.1016/S0376-8716(03)00134-0] [PMID: 12957340]
[65]
Wang PS, Berglund P, Olfson M, Pincus HA, Wells KB, Kessler RC. Failure and delay in initial treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62(6): 603-13.
[http://dx.doi.org/10.1001/archpsyc.62.6.603] [PMID: 15939838]
[66]
Buri C, Moggi F, Giovanoli A, Strik W. Prescription procedures in medication for relapse prevention after inpatient treatment for alcohol use disorders in Switzerland. Alcohol Alcohol 2007; 42(4): 333-9.
[http://dx.doi.org/10.1093/alcalc/agm038] [PMID: 17517820]
[67]
Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA 2014; 311(18): 1889-900.
[http://dx.doi.org/10.1001/jama.2014.3628] [PMID: 24825644]
[68]
Mark TL, Kassed CA, Vandivort-Warren R, Levit KR, Kranzler HR. Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend 2009; 99(1-3): 345-9.
[http://dx.doi.org/10.1016/j.drugalcdep.2008.07.018] [PMID: 18819759]
[69]
Kranzler HR, Stephenson JJ, Montejano L, Wang S, Gastfriend DR. Persistence with oral naltrexone for alcohol treatment: implications for health-care utilization. Addiction 2008; 103(11): 1801-8.
[http://dx.doi.org/10.1111/j.1360-0443.2008.02345.x] [PMID: 19032530]
[70]
Franck J, Jayaram-Lindström N. Pharmacotherapy for alcohol dependence: status of current treatments. Curr Opin Neurobiol 2013; 23(4): 692-9.
[http://dx.doi.org/10.1016/j.conb.2013.05.005] [PMID: 23810221]
[71]
Agabio R, Sinclair JMA. ‘Mother’s ruin’ – Why sex and gender differences in the field of alcohol research need consideration. Alcohol Alcohol 2019; 54(4): 342-4.
[http://dx.doi.org/10.1093/alcalc/agz053] [PMID: 31369112]
[72]
Agabio R, Pani PP, Preti A, Gessa GL, Franconi F. Efficacy of medications approved for the treatment of alcohol dependence and alcohol withdrawal syndrome in female patients: a descriptive review. Eur Addict Res 2016; 22(1): 1-16.
[http://dx.doi.org/10.1159/000433579] [PMID: 26314552]
[73]
Litten RZ, Falk DE, Ryan ML, Fertig JB. Discovery, development, and adoption of medications to treat alcohol use disorder: goals for the phases of medications development. Alcohol Clin Exp Res 2016; 40(7): 1368-79.
[http://dx.doi.org/10.1111/acer.13093] [PMID: 27184259]
[74]
Lyon J. More treatments on deck for alcohol use disorder. JAMA 2017; 317(22): 2267-9.
[http://dx.doi.org/10.1001/jama.2017.4760] [PMID: 28538998]
[75]
Witkiewitz K, Litten RZ, Leggio L. Advances in the science and treatment of alcohol use disorder. Sci Adv 2019; 5(9): eaax4043.
[http://dx.doi.org/10.1126/sciadv.aax4043] [PMID: 31579824]

Rights & Permissions Print Cite
Article Metrics
8
1
© 2024 Bentham Science Publishers | Privacy Policy